IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Farha Naz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and International Health. Hauptthemen laut MEDLINE: Interleukin-33, Immunity, Humoral, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, National institutes of Health.
Abstract (Originalsprache)
Clostridioides difficile infection (CDI) recurs in 1 of 5 patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagnosis predicts future recurrence, leading us to test the role of IL-33 signaling in the induction of humoral immunity during CDI. Using a mouse recurrence model, IL-33 was demonstrated to be integral for anti-TcdB antibody production. IL-33 acted via ST2 + ILC2 cells, facilitating germinal center T follicular helper (GC-Tfh) cell generation of antibodies. IL-33 protection from reinfection was antibody-dependent, as μMT KO mice and mice treated with anti-CD20 mAb were not protected. These findings demonstrate the critical role of IL-33 in generating humoral immunity to prevent recurrent CDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases and International Health.
- Department of Microbiology, Immunology, and Cancer Biology, and.
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- National institutes of Health
Zitieren
APA
Naz, F., Uddin, M. J., Hagspiel, N., Young, M. K., Tyus, D., Boone, R., Brown, A. C., Ramakrishnan, G., Rigo, I., Fleming, C., Madden, G. R., & Petri, W. A. (2025). IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity. Journal of Clinical Investigation. https://doi.org/10.1172/jci184659
Vancouver
Naz F, Uddin MJ, Hagspiel N, Young MK, Tyus D, Boone R, et al. IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity. Journal of Clinical Investigation. 2025. doi:10.1172/jci184659
BibTeX
@article{Naz2025,
author = {Naz, Farha and Uddin, Md Jashim and Hagspiel, Nicholas and Young, Mary K and Tyus, David and Boone, Rachel and Brown, Audrey C and Ramakrishnan, Girija and Rigo, Isaura and Fleming, Claire and Madden, Gregory R and Petri, William A},
title = {IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184659}
}
EUVIMED